People: Warner Chilcott Plc (WCRX.O)

WCRX.O on Nasdaq

25.51USD
9 Feb 2010
Price Change (% chg)

$0.30 (+1.19%)
Prev Close
$25.51
Open
--
Day's High
$25.88
Day's Low
$25.22
Volume
1,048,245
Avg. Vol
2,494,908
52-wk High
$29.24
52-wk Low
$9.24

view people for:

Summary

Name Age Since Current Position
Boissonneault, Roger 60 2005 President, Chief Executive Officer, Director
Herendeen, Paul 53 2005 Chief Financial Officer, Executive Vice President
Reichel, W. Carl 50 President - Pharmaceuticals
Fawzi, Mahdi 2009 President - Global Research and Development
Bruno, Anthony 52 Executive Vice President - Corporate Development
Hara, Izumi 49 Senior Vice President, General Counsel, Corporate Secretary
Cross, Leland 52 Senior Vice President - Technical Operations
Ellman, Herman 61 Senior Vice President - Clinical Development
Howard, Alvin 54 Senior Vice President - Regulatory Affairs
Abbrecht, Todd 40 2004 Director
Burgstahler, David 40 2004 Director
Connaughton, John 44 2004 Director
Murray, Stephen 47 2004 Director
King, John 59 2005 Director
Bloem, James 58 2006 Director
» Insider Trading

Biographies

Name Description
Boissonneault, Roger Roger M. Boissonneault was appointed President, Chief Executive Officer, Director of Warner Chilcott Ltd. as of January 5, 2005. Mr. Boissonneault was appointed Chief Executive Officer and Director of the Predecessor in September 2000. From 1996 until its acquisition by the Predecessor in September 2000, he served as President and Chief Operating Officer of the entity acquired by the Predecessor (which was also known as Warner Chilcott PLC), serving as a director from 1998 through 2000. From 1976 to 1996, Mr. Boissonneault served in various capacities with Warner-Lambert (now a part of Pfizer), including Vice President, Female Healthcare, Director of Corporate Strategic Planning and Director of Obstetrics/Gynecology Marketing.
Herendeen, Paul Paul Herendeen, Executive Vice President and Chief Financial Officer of Warner Chilcott Ltd. He joined the Company in this position on April 1, 2005 and is responsible for company's finance, accounting, treasury and management information system functions. Prior to joining the Company, Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. From 1998 through March 2001, Mr. Herendeen served as Executive Vice President and Chief Financial Officer of Warner Chilcott PLC (acquired by the Predecessor in September 2000). Mr. Herendeen also served as a director of the Predecessor from October 2000 through March 2001.
Reichel, W. Carl W. Carl Reichel, President, Pharmaceuticals of Warner Chilcott Ltd. and head of U.S. sales and marketing operations, joined the Predecessor as President, Pharmaceuticals in October 2000 after nearly 20 years of experience at Parke-Davis, a division of Warner-Lambert (now a part of Pfizer), where he, together with Mr. Boissonneault, were pioneers in the pharmaceutical marketing methods currently employed by the Company. Most recently, he held the position of President, U.K./British Isles at Warner-Lambert.
Fawzi, Mahdi Dr. Mahdi Fawzi has been appointed as President, Global Research and Development of Warner Chilcott plc. He joins Warner Chilcott from Wyeth Pharmaceuticals, where he was responsible for directing global preclinical development activities. Prior to joining Warner Chilcott, Dr. Fawzi spent nearly 15 years with Wyeth, most recently as Executive Vice President, Preclinical Development where he led the development and launch of numerous new drugs. During his tenure, he was selected as one of four finalists for the Pharmaceutical Executive of the Year award. Prior to Wyeth, Dr. Fawzi also held positions with Warner Lambert, The Procter & Gamble Company and Pfizer, Inc. Dr. Fawzi received his Bachelor of Science in Pharmacy from the University of Bagdad and his Masters and Doctorate in Pharmaceutical Chemistry from the University of Michigan.
Bruno, Anthony Anthony D. Bruno, Executive Vice President, Corporate Development of Warner Chilcott Ltd. He joined the Predecessor in March 2001 as Senior Vice President, Corporate Development and General Counsel. Mr. Bruno was promoted to Executive Vice President in April 2003 and continued to serve as General Counsel of the Company until August 1, 2005. Prior to joining the Company, Mr. Bruno spent 17 years with Warner-Lambert (now part of Pfizer) where his most recent position was Vice President and Associate General Counsel, Pharmaceuticals, and he was responsible for all legal matters relating to Warner-Lambert’s pharmaceutical business worldwide.
Hara, Izumi Izumi Hara, Senior Vice President, General Counsel and Corporate Secretary of Warner Chilcott Ltd., joined the Predecessor as Senior Vice President and Deputy General Counsel in June 2001 and is responsible for the legal matters of the Company. She was promoted to General Counsel as of August 1, 2005. Prior to joining the Predecessor, Ms. Hara held positions of increasing responsibility at Warner-Lambert (now part of Pfizer) where her most recent position was Vice President and Associate General Counsel, Corporate Affairs, where she was responsible for all corporate legal matters, including acquisitions, divestitures, alliances and other transactions in all of Warner-Lambert’s lines of business worldwide.
Cross, Leland Leland H. Cross of Senior Vice President, Technical Operations of Warner Chilcott Ltd. He joined the Predecessor in this position on September 1, 2001 and is responsible for Company's technical operations worldwide. From 1994 to 2001, Mr. Cross was part of the Global Manufacturing group at Warner-Lambert (now part of Pfizer), where most recently he was General Manager of Pfizer Ireland Pharmaceuticals, responsible for Pfizer’s dosage manufacturing operations in Ireland. Prior to joining Warner-Lambert, Mr. Cross managed a manufacturing operation for Merck & Co. Inc.
Ellman, Herman Herman Ellman, M.D., Senior Vice President, Clinical Development of Werner Chilcott Ltd. He joined the Predecessor in this position in June 2000. Dr. Ellman is responsible for clinical development and medical affairs activities. Prior to joining the Predecessor, Dr. Ellman held the position of Medical Director for Women’s Healthcare of Berlex Laboratories.
Howard, Alvin Alvin D. Howard is Senior Vice President, Regulatory Affairs of Warner Chilcott Ltd., joined the Predecessor as Vice President, Regulatory Affairs in February 2001. He was promoted to Senior Vice President as of August 1, 2005 and is responsible for the registration of all of Company's products and for managing Company's relationships with the FDA, Health Canada and other agencies regulating the sale of pharmaceutical products. Prior to joining the Company, Mr. Howard was Vice President, Worldwide Regulatory Affairs at Roberts Pharmaceuticals.
Abbrecht, Todd Todd M. Abbrecht is Director of Warner Chilcott Ltd. He is a Managing Director with Thomas H. Lee Advisors, LLC, which is the general partner of Thomas H. Lee Partners, L.P. Prior to joining Thomas H. Lee Partners in 1992, Mr. Abbrecht was in the Mergers and Acquisitions department of Credit Suisse First Boston. Mr. Abbrecht serves on the board of Simmons Company, Michael Foods, Inc., Dunkin’ Brands, Inc., and ARAMARK Holdings Corporation.
Burgstahler, David David F. Burgstahler is Director of Warner Chilcott Ltd. He is President and Head of Healthcare at Avista Capital Partners. Prior to joining Avista Capital Partners in 2005, Mr. Burgstahler was a Partner with DLJ Merchant Banking Partners, the private equity investment arm of Credit Suisse. Mr. Burgstahler joined Credit Suisse in 2000 when it merged with Donaldson, Lufkin & Jenrette. Mr. Burgstahler joined Donaldson, Lufkin & Jenrette in 1995. Mr. Burgstahler also serves on the board of Visant Corporation, WideOpenWest Holdings, Inc. BioReliance Corporation, Navilyst Medical, Inc., Lantheus Medical Imaging and ConvaTec.
Connaughton, John John P. Connaughton is Director of Warner Chilcott Ltd. He has been a Managing Director of Bain Capital Partners, LLC since 1997 and member of the firm since 1989. Prior to joining Bain Capital, Mr. Connaughton was a consultant at Bain & Company, Inc. where he worked in the healthcare, consumer products and business services industries. Mr. Connaughton currently serves as a director of Hospital Corporation of America, Clear Channel, AMC Theatres, M|C Communications (PriMed), SunGard Data Systems, Warner Music Group, CRC Health Group, Quintiles Transnational and The Boston Celtics. He also serves as a member of the Berklee College of Music Board of Trustees and the University of Virginia McIntire Foundation Board of Trustees.
Murray, Stephen Stephen P. Murray is Director of Warner Chilcott Ltd. He is the President and Chief Executive Officer of CCMP Capital Advisors, LLC, a private equity firm formed in August 2006 when the buyout/growth equity professionals of JPMP separated from JPMorgan Chase & Co. to form an independent private equity platform. Mr. Murray focuses on investments in consumer and retail services, financial services and healthcare infrastructure. Prior to joining JPMP in 1989, Mr. Murray was a Vice President with the Middle-Market Lending Division of Manufacturers Hanover. Currently, he serves on the board of directors of AMC Entertainment, ARAMARK Corporation, Cabela’s, CareMore Medical Enterprises, Generac Power Systems, Jetro Holdings, Legacy Hospital Partners (Holdings), LLC, Noble Environmental Power, Quiznos Subs and Strongwood Insurance.
King, John John A. King, Ph.D., is Director of Warner Chilcott Ltd. John A. King who became a Director of Warner Chilcott Limited in June 2005, is a private investor. Dr. King served in positions of increasing responsibility with the Predecessor for 26 years, most recently as Executive Chairman, a position he held from 2000 until January 5, 2005.
Bloem, James James H. Bloem is Director of Warner Chilcott Ltd. He is a Senior Vice President and Chief Financial Officer of Humana Inc., a position he has held since 2001. In addition, from 1996 to 2000, he served as a member of the board of directors of one of the Company's predecessor companies. Mr. Bloem also currently serves on the boards of ResCare, Inc. and Rotech Healthcare, Inc.

Basic Compensation

Name Fiscal Year Total
Boissonneault, Roger 2,062,380
Herendeen, Paul 731,412
Reichel, W. Carl 771,212
Fawzi, Mahdi --
Bruno, Anthony 745,570
Hara, Izumi 687,958
Cross, Leland 2,643,990
Ellman, Herman --
Howard, Alvin --
Abbrecht, Todd --
Burgstahler, David --
Connaughton, John --
Murray, Stephen --
King, John --
Bloem, James --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
CONNAUGHTON JOHN P 3,946,020 $22.25
BAIN CAPITAL INVESTORS L L C 3,946,020 $22.25
CONNAUGHTON JOHN P 280,128 $0.00
BAIN CAPITAL INVESTORS L L C 280,128 $0.00
CROSS LELAND H 11,230 $0.00
ELLMAN HERMAN 12,410 $0.00
HERENDEEN PAUL S 42,450 $0.00
HOWARD ALVIN D 13,000 $0.00
BRUNO ANTHONY D 42,450 $0.00
REICHEL W CARL 42,450 $0.00
BOISSONNEAULT ROGER M 144,470 $0.00
HARA IZUMI 12,410 $0.00
ELLMAN HERMAN 1,018 $14.00
HOWARD ALVIN D 1,120 $14.00
CROSS LELAND H 1,018 $14.00
ELLMAN HERMAN 1,129 $15.30
CROSS LELAND H 1,150 $15.30
HOWARD ALVIN D 1,396 $15.30
BLOEM JAMES H 2,300 $16.40
BLOEM JAMES H 200 $16.39
BURGSTAHLER DAVID F 10,000 $15.65
» Full list on Insider Trading
view people for: